The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA

被引:95
作者
Maestranzi, S
Przemioslo, R
Mitchell, H
Sherwood, RA
机构
[1] Univ London Kings Coll, Sch Med & Dent, Dept Clin Biochem, London SE5 9RS, England
[2] Univ London Kings Coll, Sch Med & Dent, Inst Liver Studies, London SE5 9RS, England
[3] Charing Cross Med Sch, Dept Oncol, London, England
关键词
pancreatic cancer; colonic cancer;
D O I
10.1177/000456329803500113
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The serum concentrations of CA19-9 and carcinoembryonic antigen (CEA) were measured in 150 consecutive patients with histologically proven liver disease admitted to a liver unit for transplant assessment. A significant proportion of the cases studied had a CA19-9 above the upper limit of the reference range (35 kU/L): alcoholic liver disease (73%), primary sclerosing cholangitis (61%), primary biliary cirrhosis (60%), chronic hepatitis B (71%), chronic hepatitis C (84%), autoimmune hepatitis (36%) and hepatocellular carcinoma (54%). CEA was only elevated in a small proportion of the patients with benign liver disease and the degree of elevation was small(15-37 mu g/L) Significantly raised CEA was observed in two patients (15%) with hepatocellular carcinoma. Statistically significant correlations were observed between the serum CA19-9 concentration and standard parameters of liver dysfunction: positive correlations with aspartate aminotransferase, alkaline phosphatase and bilirubin and negative correlations with albumin and gamma-glutamyltransferase. Positive relationships were also observed between CA19-9 and both CEA and creatinine. Both increased production of CA19-9 from biliary epithelial cells and decreased clearance due to cholestasis may be contributing to the elevation of CA19-9 in the bloodstream. Our data indicate that caution is needed in the interpretation of CA19-9 results in the presence of liver dysfunction.
引用
收藏
页码:99 / 103
页数:5
相关论文
共 15 条
[1]   ELEVATED SERUM LEVELS OF TUMOR-MARKER CA19-9 IN ACUTE CHOLANGITIS [J].
ALBERT, MB ;
STEINBERG, WM ;
HENRY, JP .
DIGESTIVE DISEASES AND SCIENCES, 1988, 33 (10) :1223-1225
[2]   EXTRAHEPATIC CHOLESTASIS DETERMINES A REVERSIBLE INCREASE OF GLYCOPROTEIC TUMOR-MARKERS IN BENIGN AND MALIGNANT DISEASES [J].
BASSO, D ;
MEGGIATO, T ;
FABRIS, C ;
PLEBANI, M ;
FOGAR, P ;
PANOZZO, MP ;
DELFAVERO, G .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1992, 22 (12) :800-804
[3]   SERUM LEVELS OF CARBOHYDRATE ANTIGENIC DETERMINANT (CA-19.9) IN OBSTRUCTIVE-JAUNDICE [J].
BENAMOUZIG, R ;
BUFFET, C ;
FOURRE, C ;
INK, O ;
MOATI, F ;
ETIENNE, JP .
DIGESTIVE DISEASES AND SCIENCES, 1989, 34 (10) :1640-1642
[4]   CA-125 (OVARIAN TUMOR-ASSOCIATED ANTIGEN) IN ASCITIC LIVER-DISEASES [J].
BERGMANN, JF ;
BEAUGRAND, M ;
LABADIE, H ;
BIDART, JM ;
BOHUON, C .
CLINICA CHIMICA ACTA, 1986, 155 (02) :163-165
[5]  
BERGMANN JF, 1987, CANCER-AM CANCER SOC, V59, P213, DOI 10.1002/1097-0142(19870115)59:2<213::AID-CNCR2820590206>3.0.CO
[6]  
2-I
[7]   CA-125 SERUM LEVELS IN PATIENTS WITH NONNEOPLASTIC LIVER-DISEASES - A CLINICAL AND LABORATORY STUDY [J].
COLLAZOS, J ;
GENOLLA, J ;
RUIBAL, A .
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1992, 52 (03) :201-206
[8]   CA-19-9 IN NONNEOPLASTIC LIVER-DISEASES - A CLINICAL AND LABORATORY STUDY [J].
COLLAZOS, J ;
GENOLLA, J ;
RUIBAL, A .
CLINICA CHIMICA ACTA, 1992, 210 (1-2) :145-151
[9]  
EERDEKENS MW, 1985, CLIN CHEM, V31, P687
[10]   CLINICAL-SIGNIFICANCE OF SERUM CA125 VALUES IN PATIENTS WITH CANCERS OF THE DIGESTIVE-SYSTEM [J].
HAGA, Y ;
SAKAMOTO, K ;
EGAMI, H ;
YOSHIMURA, R ;
MORI, K ;
AKAGI, M .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1986, 292 (01) :30-34